Powered by
CANTON TWP.—TrialAssure, a software company focused on developing clinical trial transparency tools, announced that it will offer academic institutions free access to TrialAssure Registry, its clinical trial disclosure reporting application. …
ALLENDALE—QST Consultations Ltd. has announced that it has changed its name to Abond CRO Inc., launching the new brand through a new website and participation at participation at the Summit …
FARMINGTON HILLS—Ocuphire Pharma Inc., a startup pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, announced statistically significant and clinically …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-fighting drugs, announced that its lead drug candidate, bempedoic acid, was included in the …
FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing. …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) has provided a development update for its lead drug candidate, bempedoic acid, and financial results for the first quarter ended March 31. “The potential of …
CANTON TWP. – TrialAssure, a clinical trial management software developer, announced the limited release of Anonymize.DS, an all-new software-as-a-service application that allows sponsors to anonymize clinical trial data automatically. “In …
ANN ARBOR — The pharmaceutical startup Millendo Therpeutics Inc. announced the start of a Phase 2 clinical trial of its new drug candidate ATR-101 to treat classic congenital adrenal hyperplasia …
ANN ARBOR — The pharmaceutical startup RetroSense Therapeutics LLC Monday announced the first patient in a Phase I/IIa clinical trial of its lead drug candidate, RST-001. The drug is designed …
ANN ARBOR — Cerenis Therapeutics, a French pharmaceutical startup with research and operations offices in Ann Arbor, reported Monday that two Phase II studies of its drug candidate showed positive …